These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 21861223)
1. Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Akay CL; Meric-Bernstam F; Hunt KK; Grubbs EG; Bedrosian I; Tucker SL; Kuerer HM; Hoffman KE; Babiera GV; Strom EA; Buchholz TA; Mittendorf EA Ann Surg Oncol; 2012 Mar; 19(3):901-7. PubMed ID: 21861223 [TBL] [Abstract][Full Text] [Related]
2. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Huang EH; Strom EA; Perkins GH; Oh JL; Chen AM; Meric-Bernstam F; Hunt KK; Sahin AA; Hortobagyi GN; Buchholz TA Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):352-7. PubMed ID: 16887286 [TBL] [Abstract][Full Text] [Related]
3. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334 [TBL] [Abstract][Full Text] [Related]
5. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Mittendorf EA; Buchholz TA; Tucker SL; Meric-Bernstam F; Kuerer HM; Gonzalez-Angulo AM; Bedrosian I; Babiera GV; Hoffman K; Yi M; Ross MI; Hortobagyi GN; Hunt KK Ann Surg; 2013 Feb; 257(2):173-9. PubMed ID: 23291658 [TBL] [Abstract][Full Text] [Related]
6. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy. Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263 [TBL] [Abstract][Full Text] [Related]
7. Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer. Vila J; Teshome M; Tucker SL; Woodward WA; Chavez-MacGregor M; Hunt KK; Mittendorf EA Ann Surg; 2017 Mar; 265(3):574-580. PubMed ID: 27735826 [TBL] [Abstract][Full Text] [Related]
8. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. Chen AM; Meric-Bernstam F; Hunt KK; Thames HD; Oswald MJ; Outlaw ED; Strom EA; McNeese MD; Kuerer HM; Ross MI; Singletary SE; Ames FC; Feig BW; Sahin AA; Perkins GH; Schechter NR; Hortobagyi GN; Buchholz TA J Clin Oncol; 2004 Jun; 22(12):2303-12. PubMed ID: 15197191 [TBL] [Abstract][Full Text] [Related]
9. Loco-regional control after neo-adjuvant chemotherapy and conservative treatment for locally advanced breast cancer patients. Levy A; Borget I; Bahri M; Arnedos M; Rivin E; Vielh P; Balleyguier C; Rimareix F; Bourgier C Breast J; 2014; 20(4):381-7. PubMed ID: 24890310 [TBL] [Abstract][Full Text] [Related]
10. A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy. Matsuda N; Hayashi N; Ohde S; Yagata H; Kajiura Y; Yoshida A; Suzuki K; Nakamura S; Tsunoda H; Yamauchi H J Surg Oncol; 2014 Jun; 109(8):764-9. PubMed ID: 24647874 [TBL] [Abstract][Full Text] [Related]
11. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results. Beriwal S; Schwartz GF; Komarnicky L; Garcia-Young JA Breast J; 2006; 12(2):159-64. PubMed ID: 16509842 [TBL] [Abstract][Full Text] [Related]
12. Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate. Sweeting RS; Klauber-Demore N; Meyers MO; Deal AM; Burrows EM; Drobish AA; Anders CK; Carey LA Am Surg; 2011 Jul; 77(7):850-5. PubMed ID: 21944346 [TBL] [Abstract][Full Text] [Related]
13. Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. Weksberg DC; Allen PK; Hoffman KE; Litton JK; Strom EA; Shah RR; Kuerer HM; Hunt KK; Buchholz TA; Mittendorf EA Ann Surg Oncol; 2013 Oct; 20(11):3430-7. PubMed ID: 23720073 [TBL] [Abstract][Full Text] [Related]
14. High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy. Yamazaki N; Wada N; Yamauchi C; Yoneyama K Eur J Surg Oncol; 2015 May; 41(5):617-24. PubMed ID: 25771264 [TBL] [Abstract][Full Text] [Related]
15. Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: risk factors of IBTR and validation of the MD Anderson Prognostic Index. Ishitobi M; Ohsumi S; Inaji H; Ohno S; Shigematsu H; Akiyama F; Iwase T; Akashi-Tanaka S; Sato N; Takahashi K; Oura S Cancer; 2012 Sep; 118(18):4385-93. PubMed ID: 22252882 [TBL] [Abstract][Full Text] [Related]
16. [Prognosis and risk factors of 1 791 patients with breast cancer treated with breast-conserving surgery based on real-world data]. Chen SY; Tang Y; Song YW; Wang SL; Jin J; Liu YP; Wang WH; Fang H; Ren H; Sun GY; Wang JY; Jing H; Zhang JH; Liu XF; Yu ZH; Li YX Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):619-625. PubMed ID: 30139034 [No Abstract] [Full Text] [Related]
17. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Buchholz TA; Katz A; Strom EA; McNeese MD; Perkins GH; Hortobagyi GN; Thames HD; Kuerer HM; Singletary SE; Sahin AA; Hunt KK; Buzdar AU; Valero V; Sneige N; Tucker SL Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):880-8. PubMed ID: 12095553 [TBL] [Abstract][Full Text] [Related]
18. Triple-negative breast cancer is not a contraindication for breast conservation. Adkins FC; Gonzalez-Angulo AM; Lei X; Hernandez-Aya LF; Mittendorf EA; Litton JK; Wagner J; Hunt KK; Woodward WA; Meric-Bernstam F Ann Surg Oncol; 2011 Oct; 18(11):3164-73. PubMed ID: 21947595 [TBL] [Abstract][Full Text] [Related]
19. Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis. Valachis A; Mamounas EP; Mittendorf EA; Hayashi N; Ishitobi M; Natoli C; Fitzal F; Rubio IT; Tiezzi DG; Shin HC; Anderson SJ; Hunt KK; Matsuda N; Ohsumi S; Totomi A; Nilsson C Cancer; 2018 Jul; 124(14):2923-2930. PubMed ID: 29723396 [TBL] [Abstract][Full Text] [Related]
20. Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cabioglu N; Hunt KK; Buchholz TA; Mirza N; Singletary SE; Kuerer HM; Babiera GV; Ames FC; Sahin AA; Meric-Bernstam F Cancer; 2005 Jul; 104(1):20-9. PubMed ID: 15912514 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]